FINWIRES · TerminalLIVE
FINWIRES

Ora Banda Mining Western Australia Drilling Confirms High-Grade Continuity, Expansion Potential, Euroz Hartleys Says

By

-- Ora Banda Mining (ASX:OBM) has delivered strong high-grade drilling results at its Golden Pole lode, supporting underground development potential and resource growth at the Waihi Project near the Davyhurst plant, Euroz Hartleys said in a note on Tuesday.

Targeted infill and extensional drilling in the latest 22-hole program returned results, including three meters at 44 grams per tonne grade of gold, including two meters at nearly 65 g/t grade of gold, and 11 meters at 11 g/t gold, including two meters at 48 g/t grade of gold.

The firm noted that the results de-risk Golden Pole as a near-term underground development, with consistent high-grade intercepts confirming grade continuity and mining potential.

The firm said the project's proximity to the Davyhurst plant supports low-capital intensity growth through potential reserve conversion, with Waihi increasingly seen as a third underground feed source supporting the company's production expansion strategy.

Euroz added that ongoing drilling success is expected to support a resource update and maiden underground reserve estimate targeted for the early June quarter, as the company advances its strategy to expand production through inventory growth and infrastructure leverage.

Euroz Hartleys kept a buy rating on Ora Banda Mining with a price target of AU$1.88.

Related Articles

Asia

Anteris Technologies Secures US Medicare Reimbursement Eligibility for PARADIGM Trial

Anteris Technologies (ASX:AVR) said it has secured US Medicare reimbursement eligibility for its global pivotal PARADIGM Trial under a Centers for Medicare and Medicaid Services (CMS) national coverage policy, according to a Wednesday Australian bourse filing.The PARADIGM Trial is evaluating the safety and effectiveness of the DurAVR transcatheter heart valve (THV) compared to transcatheter aortic valve replacements (TAVRs), with DurAVR THV being Anteris' product to treat aortic stenosis, a potentially life-threatening condition resulting from the narrowing of the aortic valve, the filing added.The CMS framework operates under a Coverage with Evidence Development (CED) model, enabling reimbursement with clinical evidence generation.The company said that securing this reimbursement eligibility is expected to facilitate US site activation and accelerate operational momentum across participating centers.The company's shares rose 2% in recent Wednesday trade.

$ASX:AVR
Asia

Lancang River Hydropower's 2025 Profit Rises 3%, Revenue Climbs 7%

Huaneng Lancang River Hydropower's (SHA:600025) net profit attributable to shareholders for 2025 increased 2.5% to 8.50 billion yuan from 8.30 billion yuan a year earlier, according to a Shanghai bourse filing on Wednesday.Earnings per share rose 2.3% year on year to 0.45 yuan from 0.44 yuan.Operating revenue climbed 6.9% to 26.6 billion yuan from 24.9 billion yuan in the previous year.The hydropower company's shares fell 1% during the morning trade.

$SHA:600025
Asia

Shengyi Technology's Q1 Profit Doubles as Revenue Jumps 45%

Shengyi Technology (SHA:600183) reported a 105.5% jump in attributable net profit in the first quarter to 1.16 billion yuan from 563.6 billion yuan, according to a filing with the Shanghai bourse on Wednesday.Earnings per share doubled to 0.48 yuan from 0.24 yuan.Revenue jumped 45% to 8.14 billion yuan from 5.61 billion yuan, which the electronic components manufacturer attributed to pricing adjustment, among other factors.

$SHA:600183